FREQ RSI Chart
Last 7 days
-14.3%
Last 30 days
-7.7%
Trailing 12 Months
-68.8%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2021 | 34.4M | 35.3M | 24.0M | 14.1M |
2020 | 36.8M | 44.7M | 31.7M | 37.0M |
2019 | 0 | 0 | 0 | 28.9M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Aug 21, 2023 | lucchino david l. | sold | -1,528 | 0.5 | -3,057 | president and ceo |
Aug 21, 2023 | mitrano richard j. | sold | -125 | 0.53 | -237 | vp finance & operations |
Aug 18, 2023 | lucchino david l. | sold | -1,719 | 0.6 | -2,865 | president and ceo |
Aug 18, 2023 | mitrano richard j. | sold | -143 | 0.63 | -227 | vp finance & operations |
Aug 17, 2023 | lucchino david l. | sold | -1,721 | 0.63 | -2,733 | president and ceo |
Aug 17, 2023 | mitrano richard j. | sold | -142 | 0.62 | -230 | vp finance & operations |
Aug 16, 2023 | mitrano richard j. | sold | -156 | 0.67 | -234 | vp finance & operations |
Aug 16, 2023 | lucchino david l. | sold | -1,881 | 0.65 | -2,895 | president and ceo |
Aug 15, 2023 | mitrano richard j. | sold | -148 | 0.65 | -228 | vp finance & operations |
Aug 15, 2023 | lucchino david l. | sold | -1,761 | 0.67 | -2,629 | president and ceo |
Which funds bought or sold FREQ recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Jan 16, 2024 | WEALTHSOURCE PARTNERS, LLC | sold off | -100 | -8,603 | - | -% |
May 16, 2022 | Amalgamated Financial Corp. | new | - | 8,000 | 8,000 | -% |
May 16, 2022 | Parametric Portfolio Associates LLC | reduced | -13.25 | -276,000 | 154,000 | -% |
Unveiling Frequency Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Frequency Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Frequency Therapeutics Inc News
Income Statement (Quarterly) | |||||||||||
Description | (%) Q/Q | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 |
Revenue | - | - | - | 9,417,000 | 4,651,000 | 9,950,000 | 11,247,000 | 8,523,000 | 7,264,000 | 4,709,000 | 24,238,000 |
Operating Expenses | -265.1% | -41,246,000 | 24,990,000 | 26,900,000 | 24,850,000 | 20,227,000 | 16,665,000 | 14,723,000 | 12,919,000 | 11,197,000 | 25,490,000 |
S&GA Expenses | -281.0% | -16,882,000 | 9,328,000 | 9,499,000 | 9,744,000 | 8,399,000 | 6,512,000 | 5,959,000 | 6,249,000 | 5,001,000 | 4,269,000 |
R&D Expenses | -255.6% | -24,364,000 | 15,662,000 | 17,401,000 | 15,106,000 | 11,828,000 | 10,153,000 | 8,764,000 | 6,670,000 | 6,196,000 | 5,221,000 |
EBITDA Margin | 52.9% | -1.39 | -2.96 | -1.46 | - | - | - | - | - | - | - |
Interest Expenses | 0% | 182,000 | 182,000 | 182,000 | 218,000 | - | - | - | - | - | - |
Income Taxes | -466.7% | -11,000 | 3,000 | 10,000 | - | -25,000 | 15,000 | 7,000 | 38,000 | - | - |
Earnings Before Taxes | 263.9% | 41,216,000 | -25,152,000 | -17,646,000 | -20,375,000 | -10,257,000 | -5,326,000 | -6,018,000 | -4,875,000 | -5,493,000 | -575,000 |
EBT Margin | 48.9% | -1.56 | -3.06 | -1.52 | - | - | - | - | - | - | - |
Net Income | 263.9% | 41,227,000 | -25,155,000 | -17,656,000 | -20,375,000 | -10,232,000 | -5,341,000 | -6,025,000 | -4,913,000 | -5,493,000 | -575,000 |
Net Income Margin | 48.9% | -1.56 | -3.06 | -1.52 | - | - | - | - | - | - | - |
Free Cashflow | 264.2% | 25,178,000 | -15,334,000 | -19,673,000 | - | - | - | - | - | - | - |
Balance Sheet | |||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2018Q4 |
Assets | -10.7% | 198 | 222 | 96.00 | 79.00 | 102 | 74.00 | 136 | 150 | 165 | 128 | 202 | 220 | 242 | 265 | 234 | 205 | 216 | 223 | 171 | 45.00 |
Current Assets | -15.7% | 146 | 173 | 49.00 | 48.00 | 69.00 | 57.00 | 101 | 113 | 120 | 120 | 150 | 172 | 200 | 225 | 227 | 198 | 210 | 221 | 167 | 43.00 |
Cash Equivalents | -16.5% | 139 | 166 | 46.00 | 40.00 | 41.00 | 36.00 | 48.00 | 42.00 | 50.00 | 83.00 | 112 | 135 | 169 | 40.00 | 224 | 195 | 203 | 200 | 142 | 42.00 |
Net PPE | 30.9% | 21.00 | 16.00 | 13.00 | 1.00 | 2.00 | 10.00 | 3.00 | 4.00 | 5.00 | 6.00 | 6.00 | 7.00 | 7.00 | 7.00 | 3.00 | 3.00 | 2.00 | 2.00 | 2.00 | 2.00 |
Liabilities | -9.9% | 47.00 | 52.00 | 40.00 | 34.00 | 48.00 | 9.00 | 54.00 | 54.00 | 52.00 | 6.00 | 55.00 | 54.00 | 64.00 | 72.00 | 35.00 | 43.00 | 51.00 | 56.00 | 79.00 | - |
Current Liabilities | -43.3% | 11.00 | 19.00 | 10.00 | 8.00 | 22.00 | 9.00 | 20.00 | 17.00 | 12.00 | 5.00 | 10.00 | 9.00 | 19.00 | 27.00 | 33.00 | 41.00 | 44.00 | 53.00 | 72.00 | 4.00 |
LT Debt, Current | - | - | - | - | - | 12.00 | 10.00 | 8.00 | 6.00 | 3.00 | 1.00 | - | - | - | - | - | - | - | - | - | - |
Shareholder's Equity | -10.9% | 151 | 170 | 37.00 | 45.00 | 53.00 | 69.00 | 82.00 | 96.00 | 113 | 131 | 147 | 166 | 177 | 192 | 200 | 162 | 165 | 167 | - | - |
Retained Earnings | -10.7% | -202 | -183 | -157 | -292 | -281 | -101 | -244 | -224 | -203 | -43.80 | -158 | -133 | -115 | -95.40 | -85.17 | -79.83 | -73.80 | -68.89 | -63.35 | -49.09 |
Additional Paid-In Capital | 0.3% | 354 | 353 | 4.00 | 337 | 334 | 3.00 | 327 | 321 | 316 | 2.00 | 306 | 299 | 293 | 288 | 285 | 241 | 239 | 236 | 4.00 | 1.00 |
Shares Outstanding | 0.1% | 8.00 | 8.00 | 6.00 | 36.00 | 36.00 | - | 5.00 | 35.00 | 35.00 | 5.00 | 35.00 | 34.00 | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 12.00 | - | - | - | 47.00 | - | - | - | 306 | - | - | - | 626 | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -3.7% | -21,891 | -21,107 | -23,620 | -8,424 | -14,132 | -15,033 | -7,791 | -13,478 | -17,343 | 26,077 | -15,023 | -17,674 | -25,474 | -14,833 | -10,730 | -10,262 | -9,363 | -29,742 | 74,580 | -4,472 | -6,150 |
Share Based Compensation | - | - | - | -5,174 | 2,897 | 3,431 | 235 | -8,925 | 4,564 | 5,266 | -15,779 | 5,886 | 6,089 | 4,611 | 2,765 | 2,643 | 2,411 | 2,164 | 1,153 | 925 | 1,482 | 49.00 |
Cashflow From Investing | -239.0% | -5,611 | -1,655 | -11,891 | 19,211 | 5,499 | 3,089 | 14,612 | 6,021 | -12,662 | 11,978 | -8,414 | -16,856 | -26,209 | -4,435 | -1,017 | 2,166 | 13,688 | 5,429 | 4,638 | 7,013 | -35,341 |
Cashflow From Financing | -99.9% | 139 | 144,588 | 57,308 | -11,667 | -2,468 | 14.00 | -196 | - | 200 | 114,696 | 349 | 328 | 572 | 15,383 | 40,605 | 391 | 309 | 82,198 | 59,387 | 88.00 | 342 |
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development | $ 13,572 | $ 14,694 |
General and administrative | 7,881 | 5,392 |
Total operating expenses | 21,453 | 20,086 |
Loss from operations | (21,453) | (20,086) |
Other income: | ||
Other income, net | 1,913 | 481 |
Total other income, net | 1,913 | 481 |
Loss before provision for income taxes | (19,540) | (19,605) |
Provision for income taxes | (17) | 0 |
Net loss and comprehensive loss | $ (19,557) | $ (19,605) |
Net loss per share, basic | $ (2.44) | $ (72.2) |
Net loss per share, diluted | $ (2.44) | $ (72.2) |
Weighted-average shares used in computing net loss per share, basic | 8,019,626 | 271,522 |
Weighted-average shares used in computing net loss per share, diluted | 8,019,626 | 271,522 |
Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 138,804 | $ 166,150 |
Restricted cash | 3,546 | 3,563 |
Prepaid expenses and other current assets | 3,305 | 3,015 |
Total current assets | 145,655 | 172,728 |
Property and equipment, net | 20,509 | 15,665 |
Operating lease right-of-use assets | 25,947 | 27,150 |
Restricted cash, net of current portion | 3,406 | 3,406 |
Other non-current assets | 2,468 | 2,714 |
Total assets | 197,985 | 221,663 |
Current liabilities: | ||
Accounts payable | 4,657 | 7,280 |
Accrued expenses and other current liabilities | 5,161 | 10,212 |
Operating lease liabilities, current portion | 1,235 | 1,991 |
Total current liabilities | 11,053 | 19,483 |
Operating lease liabilities, net of current portion | 34,681 | 31,216 |
Other non-current liabilities | 893 | 1,053 |
Total liabilities | 46,627 | 51,752 |
Commitments and contingencies (Note 11) | ||
Stockholders' equity | ||
Preferred stock, $0.001 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023 | 0 | 0 |
Common stock, $0.001 par value; 200,000,000 shares authorized at March 31, 2024 and December 31, 2023; 8,022,463 shares and 8,016,516 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 8 | 8 |
Additional paid-in capital | 353,912 | 352,908 |
Accumulated deficit | (202,562) | (183,005) |
Total stockholders' equity | 151,358 | 169,911 |
Total liabilities and stockholders' equity | $ 197,985 | $ 221,663 |